Northwest Biotherapeutics, ordinary share
0K95, US66737P6007

Northwest Biotherapeutics, Inc. is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach in developing cancer therapies utilizes its ...

Northwest Biotherapeutics, Inc. is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. It focused on advancing a dendritic cell immunotherapy for prostate and brain cancer. The Company has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform.